Biomarker Discovery and Validation in Lung Cancer (LCS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01147562

Recruitment Status : Active, not recruiting

First Posted : June 22, 2010

Last Update Posted : February 1, 2019

Sponsor:

Collaborators:

Integrated Biobank of Luxembourg

Centre Hospitalier du Luxembourg

Information provided by (Responsible Party):

Dr. Guy Berchem, Public Research Centre Health, Luxembourg

Study Description

Brief Summary:

Lung cancer is responsible for the most deaths due to cancer each year in both men and women worldwide and once diagnosed, the 10 year survival rate is poor (<15%). This poor prognosis is based in large part on the absence of an effective diagnostic test for the disease. The chief objective of this study is to develop a molecular-based diagnostic test specific for lung cancer. Subjects suspected or diagnosed with lung cancers, who are either undergoing thoracentesis, biopsy of a suspicious lesion or surgical resection of their tumor will be asked to participate in this study. Those subjects, who will undergo surgical resection, will donate both lung tumor tissue and adjacent normal lung tissue (potentially including lymph nodes), while non-surgical candidates will donate a portion of their excess biopsy sample, if available, after diagnosis has been confirmed. Subjects undergoing thoracentesis for pleural effusion will donate a portion of their fluid sample, if the fluid volume collected is in excess of that needed for clinical care purposes. Blood samples and optionally saliva will also be collected from all subjects, whether undergoing surgery or not. In addition to biosample collection, detailed annotated demographic and clinical information will be collected from subjects. Subjects will be followed for outcome analysis, specifically for tumor recurrence, every 6 months, during 5 years. In case of change in chemotherapy treatment, biosamples and clinical information will also be collected. Collected biosamples will be analyzed using a series of molecular and proteomic technologies for developing biomarkers of the disease.

Condition or disease	Intervention/treatment	Phase
Lung Cancer	Procedure: Collection of biospecimen	Not Applicable

Detailed Description:

The primary objective of this study is to discover and validate molecular biomarkers for lung cancer.

Lung cancer remains the leading cause of cancer death in industrialized countries. Most patients with non-small cell lung cancer (NSCLC) present with advanced disease, and despite recent advances in multi-modality therapy, the overall 10-year survival rate is less than 10%. A significant minority of patients (25−30%) with NSCLC have stage I disease and receive surgical intervention alone. Although 35−50% of patients with stage I disease will relapse within 5 years, it is not currently possible to identify specific high-risk patients. In addition, for patients with metastatic disease, standard chemotherapeutic approaches result in less than 50% response rate, meaning that more than half of patients do not benefit and only suffer from side effects.

Only very limited data exists on markers capable of predicting response to chemotherapy.

This population would certainly also benefit from more of those markers. Another situation where a biomarker could be potentially very useful is the situation where a pulmonary nodule is diagnosed and has to be characterized. In this situation a biomarker could predict whether the nodule is or is not cancerous and thus, make CT Scan follow up unnecessary.

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	150 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Other
Official Title:	Biomarker Discovery and Validation in Lung Cancer
Actual Study Start Date :	October 14, 2009
Estimated Primary Completion Date :	July 2020
Estimated Study Completion Date :	October 2020

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Lung cancer

MedlinePlus related topics: Lung Cancer

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Lung Cancer Patients Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor	Procedure: Collection of biospecimen Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.

Outcome Measures

Primary Outcome Measures :

Discover and validate molecular biomarkers for lung cancer [ Time Frame: Participants are followed up very 6 months up to to 5 years or until death. ]
Investigate markers capable of prediciting response to chemotherapy. In cas a pulmonary nodule is diagnosed and has to be characterized, a biomarker could predict whether the nodule is or is not cancerous and thus, make CT Scan follow up unnecessary.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor

Exclusion Criteria:

Pregnant women
Minors (subjects less than 18 years of age)
Prisoners
Subjects unable to consent for themselves

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01147562

Locations


Luxembourg
Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg, 1210
Clinique Sainte Thérèse (Zithaklinik)
Luxembourg, Luxembourg, L-2763

Sponsors and Collaborators

Dr. Guy Berchem

Integrated Biobank of Luxembourg

Centre Hospitalier du Luxembourg

Investigators


Principal Investigator:	Guy Berchem, MD	Centre Hospitalier du Luxembourg

More Information

Publications:

Dziadziuszko R, Hirsch FR. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. Clin Lung Cancer. 2008 Mar;9(2):78-84. doi: 10.3816/CLC.2008.n.012. Review.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8.


Responsible Party:	Dr. Guy Berchem, MD, Public Research Centre Health, Luxembourg
ClinicalTrials.gov Identifier:	NCT01147562 History of Changes
Other Study ID Numbers:	IBBL0001
First Posted:	June 22, 2010 Key Record Dates
Last Update Posted:	February 1, 2019
Last Verified:	January 2019

Keywords provided by Dr. Guy Berchem, Public Research Centre Health, Luxembourg:


Lung cancer Biopsy Biomarker Tissue Collection

Additional relevant MeSH terms:


Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site	Neoplasms Lung Diseases Respiratory Tract Diseases

To Top